The FDA has rejected Novo Nordisk's once-weekly insulin icodec. In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024. https://hubs.li/Q02Grm2J0 #pharma #biospace
BioSpace
Internet News
West Des Moines, Iowa 112,670 followers
The leading source for biopharma news and jobs. Connecting industry pioneers with talented professionals.
About us
BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.
- Website
-
http://www.biospace.com/
External link for BioSpace
- Industry
- Internet News
- Company size
- 11-50 employees
- Headquarters
- West Des Moines, Iowa
- Type
- Privately Held
- Founded
- 1985
- Specialties
- biotech jobs, pharma jobs, biotech news, pharma news, and life sciences news
Locations
-
Primary
3001 Westown Pkwy
#101
West Des Moines, Iowa 50266, US
Employees at BioSpace
-
Greg Slabodkin
-
Dr. D. Martin Alexander Gershon, MD, JD, MPH
AI & Digital Health Innovation Keynote•Linkedin “Top Voice” Venture Capital, Entrepreneurship, & Fundraising•Techstars Sr EIR•Goldman…
-
Angela Gabriel
Content Manager (Life Sciences Careers) at BioSpace
-
Lori Ellis (Katz)
Head of Insights
Updates
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs. Today, we cover Spark Therapeutics, Inc., Novartis, Indivior and more as they cut staff. https://hubs.li/Q02Grwtz0 #pharma #layoffs #biospace
Biopharma Layoff Tracker 2024: Spark, Novartis, Indivior and More Cut Staff | BioSpace
biospace.com
-
The Senate on Thursday unanimously passed a bill aimed at limiting the number of patents drugmakers can introduce and making it easier for generic and biosimilar competitors to enter the market. https://hubs.li/Q02Gnbf-0 #pharma #legislature #Senate #biospace
Senate Unanimously Passes Bill to Reduce Big Pharma Patent Thickets, Increase Competition | BioSpace
biospace.com
-
Immutep Limited shares jumped nearly 20% on Friday after data showed its LAG-3 therapy—plus Keytruda—elicited strong response rates in head and neck squamous cell carcinoma patients in the front-line setting. https://hubs.li/Q02GmWQm0 #pharma #biospace
Immutep Aces Phase IIb in First-Line Head and Neck Cancer, Eyes Regulatory Path Ahead | BioSpace
-
CVS Health Caremark’s recent decision to take AbbVie's Humira off its major formularies has caused the blockbuster to lose more market share to biosimilars, according to the latest report from Samsung Bioepis. https://hubs.li/Q02GmVFc0 #pharma #biospace
AbbVie’s Humira Continues to Lose Market Share as Biosimilars Gain Ground: Report | BioSpace
-
Akebia Therapeutics on Thursday said it regained full U.S. rights to its chronic kidney disease anemia drug Vafseo, which the biotech has priced at around $15,500 per year. https://hubs.li/Q02Gm6330 #pharma #biospace
Akebia Ends Deal With CSL Vifor, Unveils Hefty Price Tag for CKD Anemia Drug Vafseo | BioSpace
biospace.com
-
Swiss pharma Novartis has let go of 29 employees in San Diego and will eliminate approximately 100 more jobs as it winds down its research site there. Follow along as we keep you up to date on which companies are tightening their belts and cutting staff. #layoffs #biospace https://hubs.li/Q02GfhTM0
Biopharma Layoff Tracker 2024: Novartis, Indivior, Apollomics and More Cut Staff | BioSpace
biospace.com
-
In its second antibody-drug conjugate licensing agreement this year, Ipsen has secured exclusive rights to Foreseen Biotechnology’s FS001, which targets a novel antigen expressed across a range of solid tumors. #biospace https://hubs.li/Q02Gfwx40
Ipsen Inks Potential $1B First-in-Class ADC Deal With Foreseen | BioSpace
biospace.com
-
In its second antibody-drug conjugate licensing agreement this year, Ipsen has secured exclusive rights to Foreseen Biotechnology’s FS001, which targets a novel antigen expressed across a range of solid tumors. #biospace https://hubs.li/Q02GfbGg0
Ipsen Inks Potential $1B First-in-Class ADC Deal With Foreseen | BioSpace
biospace.com
-
Kazia Therapeutics Limited is eyeing an FDA accelerated approval pathway for its investigational glioblastoma drug paxalisib, with Wednesday’s release of secondary overall survival data from a Phase II/III trial. #Pharma #biospace https://hubs.li/Q02Gc0ff0
Kazia Offers Secondary OS Data to Build FDA Case for Glioblastoma Drug | BioSpace
biospace.com